AniLocus
Private Company
Total funding raised: $4.5M
Overview
AniLocus is a privately held, preclinical CRO founded in 2020 and headquartered in Cambridge, Massachusetts, with a laboratory facility in Germantown, Maryland. The company operates a services-based business model, generating revenue by providing outsourced research services including in vivo studies, behavioral phenotyping, bioanalytical assays, and custom equipment design for clients in the gene therapy and rare disease sectors. As a specialized service provider, AniLocus focuses on enabling external therapeutic programs rather than developing its own drug pipeline, positioning itself as a key partner in the preclinical development ecosystem.
Technology Platform
Integrated preclinical research service platform featuring in vivo study execution, behavioral neuroscience assays, bioanalytical testing, and in-house custom apparatus design and fabrication.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
AniLocus competes in the fragmented preclinical CRO market, facing large global players (e.g., Charles River Laboratories, Labcorp) with broad resources and smaller niche specialists. Its differentiation lies in the integration of custom hardware fabrication with behavioral neuroscience expertise, a combination not commonly offered, which targets a specific segment of clients needing highly tailored preclinical study solutions.